Despite the wealth of information supporting the contribution of TLR4 and the NLRP3 inflammasome to the pathophysiology of hyperuricaemia nephropathy, clinical application of therapies targeting these pathways remains unachieved. The gene discussed is TLR4; the disease is hyperuricemia.